Search
Avibactam
go.drugbank.com/drugs/DB09060ApprovedInvestigationalAs there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options. … This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract
Products: ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 2G/0.5GClofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to ...
Products: EVOLTRA 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION, NUCLOFAR Clofarabine 1mg/mL Concentrate for Solution for InfusionPertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.
Products: Perjeta 420 mg concentrate for solution for infusion, PERJETA CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/14MLEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. … It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)Antithymocyte immunoglobulin (rabbit)
go.drugbank.com/drugs/DB00098ApprovedInvestigationalThymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients.
Products: Thymoglobuline 5mg/ml Powder for concentrate for solution for infusionDoxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigationalDoxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxor...
Synonyms: MTC-DOX for InjectionProducts: DOXABIN POWDER FOR SOLUTION FOR INJECTION 10MG/VIAL, DOXABIN POWDER FOR SOLUTION FOR INJECTION 50MG/VIALEpoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary...
Products: VELETRI POWDER FOR SOLUTION FOR INFUSION 0.5MG/VIAL, VELETRI POWDER FOR SOLUTION FOR INFUSION 1.5MG/VIALFondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalThe monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII).
Products: ARIXTRA 12.5MG/ML SOLUTION FOR INJECTION, ARIXTRA 2.5MG/0.5ML SOLUTION FOR INJECTIONTozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigationalIt is designed to induce immunity against SARS-CoV-2, the virus responsible for causing COVID-19. … [L26956] Fact sheets for caregivers, recipients, and healthcare providers are now available.
Products: Comirnaty 3mcg Concentrate for Dispersion for Injection, Comirnaty Omicron XBB.1.5 10 micrograms/dose Dispersion for InjectionPegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigational[A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer … [L9974] NIOPEG (pegfilgrastim), a biosimilar of NEULASTA®, was approved by Health Canada in April 2024 for the prevention of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive
Products: Pelgraz 6 mg solution for injection in a pre-filled syringe, Pelgraz Solution for Injection in pre-filled syringe 6mg/0.6mL